465 related articles for article (PubMed ID: 32999291)
1. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
[TBL] [Abstract][Full Text] [Related]
2. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles.
Rao L; Zhao SK; Wen C; Tian R; Lin L; Cai B; Sun Y; Kang F; Yang Z; He L; Mu J; Meng QF; Yao G; Xie N; Chen X
Adv Mater; 2020 Nov; 32(47):e2004853. PubMed ID: 33089578
[TBL] [Abstract][Full Text] [Related]
3. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
4. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer.
Kulkarni A; Chandrasekar V; Natarajan SK; Ramesh A; Pandey P; Nirgud J; Bhatnagar H; Ashok D; Ajay AK; Sengupta S
Nat Biomed Eng; 2018 Aug; 2(8):589-599. PubMed ID: 30956894
[TBL] [Abstract][Full Text] [Related]
5. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
7. Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy.
Tang L; Yin Y; Cao Y; Fu C; Liu H; Feng J; Wang W; Liang XJ
Adv Mater; 2023 Sep; 35(35):e2303835. PubMed ID: 37384818
[TBL] [Abstract][Full Text] [Related]
8. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
[No Abstract] [Full Text] [Related]
10. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
11. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
12. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
13. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
[TBL] [Abstract][Full Text] [Related]
14. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
16. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
17. Engineered CD47 protects T cells for enhanced antitumour immunity.
Yamada-Hunter SA; Theruvath J; McIntosh BJ; Freitas KA; Lin F; Radosevich MT; Leruste A; Dhingra S; Martinez-Velez N; Xu P; Huang J; Delaidelli A; Desai MH; Good Z; Polak R; May A; Labanieh L; Bjelajac J; Murty T; Ehlinger Z; Mount CW; Chen Y; Heitzeneder S; Marjon KD; Banuelos A; Khan O; Wasserman SL; Spiegel JY; Fernandez-Pol S; Kuo CJ; Sorensen PH; Monje M; Majzner RG; Weissman IL; Sahaf B; Sotillo E; Cochran JR; Mackall CL
Nature; 2024 Jun; 630(8016):457-465. PubMed ID: 38750365
[TBL] [Abstract][Full Text] [Related]
18. Anti-SIRP
Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
[TBL] [Abstract][Full Text] [Related]
19. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
